Researchers have launched a phase I clinical trial investigating a novel approach called bipolar androgen therapy (BAT) for patients with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has stopped responding to standard hormone-lowering treatments. The trial, registered on ClinicalTrials.gov, aims to explore whether deliberately cycling testosterone levels between very low and very high points in the body can help re-sensitize cancer cells to androgen deprivation therapy.
Bipolar androgen therapy works by alternating testosterone exposure between castration levels—lower than what the body normally produces—and supraphysiological levels, which are higher than typical. This unconventional strategy is based on the idea that rapidly shifting hormone levels may confuse or stress prostate cancer cells that have adapted to survive in a low-testosterone environment, potentially making them vulnerable again to treatments that were previously effective.
The phase I study will primarily examine changes in androgen receptor sensitivity, along with safety and early signs of effectiveness. Researchers will monitor prostate-specific antigen (PSA) levels, a key biomarker used to track prostate cancer activity, to see whether the therapy can help suppress cancer cell growth and potentially delay disease progression in this hard-to-treat patient population.
This research represents an encouraging step forward for patients with mCRPC, a stage of prostate cancer that often presents significant treatment challenges once resistance to standard therapies develops. If bipolar androgen therapy proves both safe and effective at restoring treatment sensitivity, it could open new avenues for combination treatment strategies, potentially extending the usefulness of existing androgen deprivation therapies rather than requiring entirely new drug classes.
Early-phase trials like this one are essential building blocks in cancer research, helping scientists understand whether creative, mechanism-based approaches can translate into real clinical benefit. As this study progresses, it will contribute valuable data to the broader effort to improve outcomes for men facing advanced prostate cancer. This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply